Vicore Pharma Holding AB · OMXSTO:VICO
Vicore Pharma Holding AB — Q3 2026 Earnings Presentation
21 slides from Vicore Pharma Holding AB's earnings presentation, Nov 5, 2026
Slide 1: Interim report July 1 - September 30, 2026
vcore pharma Interim report July 1- September 30, 2026 Vicore Pharma Holding AB (publ)
Slide 2: Contents
Summary of the Period CEO Comments Pipeline Financial Information. Sustainability at Vicore Other Information. Interim Condensed Consolidated Financial Statements - Group Financial Reports ~ Parent Company, Notes Key Performance Measures. Contact Information
Slide 3: Summary of the Period
: the Period Significant events during the third quarter © In July, vicore's American Depositary Shares com- ‘menced trading on the Nasdaq Capital Market in the United States under the ticker symbol 'VCRE". The USS Listing sa dual isting that complements Vicore's existing listing on Nastag Stockholm
Slide 4: CEO comments
CEO The third quarter was a period of disciplined execution as ASPIRE advances toward its 52-week readout. Shortly after the period ended, the independent Data Monitoring Committee recommended that ASPIRE continue as planned following a pre-planned futility analysis, keeping us on track for topline
Slide 5: CEO comments continued: ASPIRE and clinical engagement
arrive, we intend to be ready to proceed rather than to begin planning, During the quarter, we also continued to deepen our engagement with the Clinical community. Atthe European Respiratory Society Congress in Barcelona in September, Professor Toby ‘Maher presented the design of ASPIRE ‘and the bas
Slide 6: Financial information: net revenues and operating expenses
Net revenues illion and 26 and 2025, ss were SEK 3.4 million and SEK 3.4 million for the nine months ‘and vely. Net revenues are related to reimbursement for incurred by the developr buloxibutid under the license agreement with Nippon Shinyaku. Operating expenses Operating expenses w milion and SEK
Slide 7: Financial information continued
‘ended September 30, 2026 and 2025, this ratio was 79.0 percent and 85.5 percent, respectively. Other operating income and expenses Other operating income (expenses), net was (SEK 0.2 milion) and SEK (0.1 million forthe three months «ended September 30, 2026 and 2025, respectively. Other operating i
Slide 8: Sustainability at Vicore
? Sustainability : at Vicore Vicore's mission to develop life-changing therapies for severe fibrotic diseases is grounded in a commitment to sustainability, social responsibility, and ethical leadership. As we continue to expand our clinical programs and advance our pipeline, we remain committed to
Slide 9: Other information
Other Personnel As of September 30, 2026, the group had 50 employees: 17 men (Septembe of shares, The company's mpany has oné women and 30,202: employees, 25 women and 11 men). Of 105, 4 were active in RED (September 30,2025:27). The grou Iso frequently engage: Atthe Annual General Meeting o May 6,2
Slide 10: Board and CEO assurance
Ind the CEO assure that the interim ialpo: gent compat ced by the npany and the companies in the group, ‘Stockholm, November 5, 2026 Heidi Hunt nembe unterberg Peter Guenter ember i Al Wakeel ‘Ahmed Mousa ember cEO 10 | VoorePamatkang 8 aterm Report, 3 2025,
Slide 11: Interim Condensed Consolidated Financial Statements - Group
: Group Condensed Consolidated Statements of Comprehensive Income (Loss) Interim Condensed Consolidated Financial Statements Condensed Consolidated Statements of Financial Position (SEK nthousands except per share amount or a8 2026 ©2025-2026 «= 20252025 otherwise indeated) Jul-Sep Jul-Sep _Jan-Sep_
Slide 12: Changes in Shareholders' Equity and Cash Flows
Condensed Consolidated Statements of Changes in Shareholders’ Equity Condensed Consolidated Statements of Cash Flows ‘Shareholders’ equity attributable to the parent ‘company 2026 ©2025 «2026 «= 20252025 (SEKin thousands) Jul-Sep Jul-Sep _Jan-Sep _Jan-Sep__Jan-Dec. Equity atthe beginning ofthe perio
Slide 13: Financial Reports: Parent Company
: Financial Reports Parent Company Parent Company's Income Statement 2026 2025 2026 2025 2025 (SEKin thousands) Jul-Sep Jul-Sep __Jan-Sep_Jan-Sep__Jan-Dec. Net revenues 20005 15604 63210 orsss 114873 ‘Gross income 20025 15,694 «63210 67,554 114,973 Administrathve expenses (sam) (17.162) (@s656) (44.
Slide 14: Parent Company's Balance Sheet
Parent Company's Balance Sheet Parent Company's Balance Sheet 2026 2025 2025 2026 2025 2025 (SEKin thousands) Sep30_Sep30_—— Dec 31 (SEKinthousands) Sep30__Sep30___—Dec31 ASSETS EQUITY AND LIABILITIES Fined assets Partcipations in group companies 22sasso 1988112 __1939;390 ved “Total fixed assets 22
Slide 15: Notes
: Notes Note 1. General information ‘Theiinterim condensed consolidated financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. The group ‘operates as a single operating segment, ‘and the Chief Executive Officer isthe Chie operating decision maker. This report
Slide 16: Notes: risks
in identifying and recruiting patients for studies, patients not completing a study F not returning for follow. events outside Vicore’s dependent on partners fo manufacturing ands p,orothes rol. View ly chain risks. Patents that the c for may not be granted a patents may b loss of patent prote prod
Slide 17: Note 7. Share-based incentive programs
Note 7. Share-based incentive programs “The purpose of share based incentive programs isto promote the company’s long term interests by motivating and rewarding ‘senior management, employees and board members in ways that align with shareholders’ interests. ‘Vicore currently has eight programs with
Slide 18: Key performance measures
Vicore applies the guidelines issued by ESMA (European Securities and Markets Authority) for alternative performance measures (APM). APMs are financial measurements of historical (r future earnings, financial position, financial results or cash flows that are not defined or specified inthe appli abl
Slide 19: Definitions and reconciliation of alternative performance measures
Definitions and reconciliation of alternative performance measures Alternative performance measures Definition Justification Equityratio Total shareholders equiy divided by total The company believes that this key ratio provides investors assets with useful information regarding the companys capital
Slide 20: Contact Information
. : Contact 4 . : Information Address: Contact ve Phang sonst a Hans Jeppson, CFO Tek: +46 (0)70 9531465 hans jeppsson@vicorepharma.com Tek: +46 (0)31 788 05 60 (Org.no.: 56680-3804 ‘www-vicorepharma.com This interim report has been prepared originally in Swedish and has been translated into English
Slide 21: Vicore Pharma
vcore pharma Vicore Pharma Holding AB Kornhamnstorg 53, SE-111 27 Stockholm, Sweden | +46 (0)31 788 05 60 | vicorepharma.com
Vicore Pharma Holding — Q3 2026 Earnings Presentation on 6ix